SG Americas Securities LLC bought a new stake in AstraZeneca PLC (OTCMKTS:AZNCF – Free Report) in the 1st quarter, Holdings Channel.com reports. The fund bought 8,013 shares of the company’s stock, valued at approximately $1,580,000.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Hughes Financial Services LLC bought a new stake in shares of AstraZeneca during the fourth quarter worth $34,000. Fairscale Capital LLC bought a new position in AstraZeneca in the fourth quarter valued at about $37,000. Mascoma Wealth Management LLC bought a new position in AstraZeneca in the fourth quarter valued at about $46,000. Aventus Investment Advisors Inc. acquired a new stake in AstraZeneca in the first quarter worth about $46,000. Finally, Resources Management Corp CT ADV acquired a new stake in AstraZeneca in the fourth quarter worth about $61,000. 40.87% of the stock is owned by institutional investors and hedge funds.
AstraZeneca Price Performance
Shares of OTCMKTS:AZNCF opened at $187.10 on Friday. AstraZeneca PLC has a 1-year low of $122.26 and a 1-year high of $195.00. The business has a 50-day moving average price of $187.10 and a two-hundred day moving average price of $186.46.
AstraZeneca Company Profile
AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.
The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.
Featured Stories
- Five stocks we like better than AstraZeneca
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Want to see what other hedge funds are holding AZNCF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (OTCMKTS:AZNCF – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
